Q-omics provides the consensus-scored RUVBL1 profile across patient tissues and cancer cell-line models. RUVBL1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RUVBL1 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, RUVBL1 protein abundance shows 27,788 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, HNSC, and LSCC as cancer lineages where RUVBL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RUVBL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RUVBL1 survival associations across molecular data types. RUVBL1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RUVBL1 RNA expression–survival associations across cancer types. High RUVBL1 expression shows unfavorable associations in MESO, ACC, LIHC, LUAD and LGG, but favorable associations in UVM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RUVBL1 RNA expression.
This table summarizes RUVBL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 7. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RUVBL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RUVBL1 shows higher tumor expression in HNSC, COAD, BLCA, LUAD, STAD and LIHC. The HNSC box plot shows higher RUVBL1 RNA expression in tumor versus normal tissue (log2 FC = +1.795, t-test p < 0.001).
This table shows molecular features associated with RUVBL1 in patient tissues and cancer cell lines. In patient samples, RUVBL1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RUVBL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
